Unichem Laboratories on Monday reported a standalone net profit of Rs 25.07 billion for the third quarter ended December 31, mainly on account of sale of the company's domestic pharma business in India and Nepal to Torrent Pharmaceuticals.
Standalone total income stood at Rs 1,658.2 million for the quarter under review. It was at Rs 1,598.2 million for the same period a year ago.
The company also said its board has approved the buyback proposal for the purchase of its 20.6 million equity shares for an aggregate amount not exceeding Rs 8,858 million from the shareholders of the company.
The board noted the intention of the promoters and promoter group of the company to participate in the proposed buyback.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)